Warning Letter — Zhejiang Gaorong Cosmetic Co., Ltd.
The FDA issued a warning letter to Zhejiang Gaorong Cosmetic Co., Ltd. following an evaluation by the Center for Drug Evaluation and Research (CDER). The source indicates the letter was issued on October 1, 2026, though specific regulatory violations are not detailed in the provided excerpt.
This notice affects Zhejiang Gaorong Cosmetic Co., Ltd., its manufacturing and quality departments, and potentially its distributors or partners within the cosmetic and drug sectors.
An issuance from CDER to a cosmetic company suggests that the facility may be manufacturing products that fall under drug regulations (such as OTC products) or that significant CGMP deviations were identified. This likely implies a period of heightened regulatory scrutiny, potential import alerts, or the necessity for significant remediation of quality management systems to maintain U.S. market access.
Firms should conduct a comprehensive gap analysis of current manufacturing and testing procedures against CGMP standards, ensuring that products marketed in the U.S. meet both cosmetic and relevant drug requirements if applicable. Regulatory teams should verify that all facility registrations and product listings are current and accurate.
FDA Warning Letter issued to: Zhejiang Gaorong Cosmetic Co., Ltd.. 10/01/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/zhejiang-gaorong-cosmetic-co-ltd-732511-10012026
Open in openFDA / FDA.gov